Skip to main content

Julie Dumond

Assistant Professor

Julie Dumond, Pharm.D., M.S.

Assistant Professor


julie_dumond

PHONE
(919) 966-5017
EMAIL
jdumond@unc.edu
ADDRESS
1093 Genetic Medicine Building, 120 Mason Farm Road, CB# 7361, Chapel Hill, NC, 27599
DOWNLOAD CV

Julie Dumond is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Her primary research interest is the pharmacokinetics/pharmacodynamics of antiretrovirals for HIV treatment and prevention. She is Chair of the MACS/WIHS Combined Cohort Study Pharmacology Working Group, and is currently conducting a study of intracellular tenofovir pharmacology within the cohort (R21AG058490). She also serves as the HIV Prevention Trials Network Pharmacologist on four NIH-sponsored early-phase studies of HIV broadly neutralizing antibodies for HIV prevention. She also has an interest in the influence of cellular and biologic aging on antiretroviral PK/PD and immunologic recovery of persons living with HIV.

Dumond directs the first module in the DPET graduate pharmacokinetics/pharmacodynamics curriculum, DPET 853, and is one of the DPET Division Directors for the Research and Scholarship in Pharmacy (RASP) program for Doctor of Pharmacy students.

Dr. Dumond’s translational research program aims to improve treatment and prevention of HIV infection through application of pharmacokinetic/pharmacodynamic principles. In addition to working in the federally-funded MACS/WIHS Clinical Cohort Study, she and her team often conduct smaller, investigator-initiated PK/PD studies in the UNC Clinical and Translational Research Center in healthy volunteers and people living with HIV. Dr. Dumond has broad expertise in antiretroviral clinical pharmacology, including PK/PD, drug-drug interactions, and intracellular disposition of the nucleoside reverse transcriptase inhibitors. Topics of current focus include:

  • Influence of Biologic Aging and Inflammation on Tenofovir/Emtricitabine Intracellular Pharmacology
  • Sex Differences in Antiretroviral Adverse Effects
  • Determining the At-Risk Phenotype for Integrase-Inhibitor-Mediated Weight Gain and Cardiometabolic Adverse Effects
  • Renal and Bone Safety of Tenofovir Alafenamide in Aging People Living with HIV

In addition, Dr. Dumond also has a growing interest in educational research and best practices for teaching quantitative skills in pharmacokinetics.

  • Effects of Aging and Inflammation on Intracellular Nucleoside Reverse Transcriptase Inhibitor Pharmacology in the WIHS Cohort
  • Interaction of Nucleoside Reverse Transcriptase Inhibitor Pharmacology and Aging in the Multicenter AIDS Cohort Study

  • 2012- Master of Science, Pharmaceutical Sciences, State University of New York at Buffalo
  • 2004- Doctor of Pharmacy, University of Michigan College of Pharmacy
  • 2000- Bachelor of Science, Physical Sciences, Michigan State University
  • 2006- Board Certified Pharmacotherapy Specialist (BCPS)
  • 2004-2005: Pharmacy Practice Residency, Borgess Health, Kalamazoo, MI
  • 2005-2007: HIV Pharmacology Fellowship, UNC Eshelman School of Pharmacy